Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 26, 2019
Daily News
December 26, 2019
- Top 10 PHARMA JAPAN Articles in 2019
December 26, 2019
- AMED’s Kono Tapped to Lead Medical Device Review at MHLW
December 26, 2019
- Xofluza Most Detailed Drug for GPs in November: Impact Track
December 26, 2019
- Japan's Global Health Confab to Prepare New Grand Design for Regulatory Harmonization in Asia
December 26, 2019
- IBL Inks Tick-Borne Disease Deal with South Korea Firm
December 26, 2019
- Nippon BI Chair Thorsten Poehl to Double as President after Merger; Yoshiaki Aono to Head Pharma Biz
December 26, 2019
- Fujifilm PII Alzheimer’s Study Gets Underway in Europe
December 26, 2019
- Opdivo/Yervoy Combo Filed for Frontline NSCLC in Japan
December 26, 2019
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…